Head, Biomarker Development

The Bluefield Project to Cure Frontotemporal Dementia

The Bluefield Project to Cure Frontotemporal Dementia (FTD) is a research foundation focused on developing a cure for FTD caused by mutations in the progranulin gene. The Foundation also manages the Consortium for Frontotemporal Dementia Research (CFR), a network of academic researchers that has made breakthroughs in understanding the genetics, biology and clinical manifestations of progranulin-deficient frontotemporal dementia.

We have made rapid progress at identifying potential therapies through basic science research. We are now expanding our focus to better characterize the course of the disease so we can evaluate the effects of therapies in treating FTD. To this end, we are looking for a motivated individual to lead our Biomarker Program.


The successful candidate will develop an approach to discover and validate the most promising biomarkers of disease in collaboration with our scientific and medical colleagues. This person will lead the project team that will make the case before the FDA, and perhaps other regulatory bodies, to reach consensus on the appropriate biomarker for use in measuring the treatment effect of therapeutic agents on disease.

This person will work with scientists, clinicians, Key Opinion Leaders and consultants to develop the appropriate strategy and implement the plan. The position will report to the President of the Bluefield Project.

The successful candidate will need to identify resources - both within the academic consortium and outside – to make and execute their plan. He or she will need to interact with and manage contract research organizations (CRO’s) as part of this plan, and be able to evaluate and bring new technologies into the program, as appropriate.


The successful candidate will have an advanced degree (PhD or MD or equivalent) in the biological sciences, with a strong background in protein biochemistry, nucleic acid analyses, bioanalytics, the various ‘omics (including proteomics, genomics and lipidomics) or equivalent. Knowledge of the types of assays and approaches to biomarker development and their analyses is essential. Strong written and oral communication skills and experience working with the FDA is highly advantageous.

Familiarity with orphan drugs and their approval process is desirable. Experience with neurological disorders and venture philanthropy is advantageous but not required.

Please send applications to Dr. Rodney Pearlman, President, at